February 2, 2018

Adherence: Enhanced Studies Through Medsmart

Adherence

Our CMO Scott Crae examines how the Medsmart platform can transform Pharma Co adherence studies from retrospective to pro-active campaigns.

ADHERENCE

‘Factors associated with better persistence included older age, male sex, white ethnicity, HbA1c 42-60 mmol/mol, presence of hypertension, no previous glucose-lowering medication use. Non-persistence (was) associated with presence of neuropathy, history of myocardial infarction, heart failure, dementia, depression, and chronic liver disease.’ Medication non-persistence was defined as a ‘prescription gap’ of greater than or equal to 90 days. Non-adherence was identified in 68.5% of study participants, with a median duration of non-adherence of 2.25 years. Metformin drugs such as Glucophage, were found to have the longest crude persistence. Digital tools such as Medsmart®, which provides continuous real-world data insights and patient communication, can enable retrospective studies such as these to become pro-active campaign tools, and deliver the vital information that such studies provide on an ongoing basis. The Medsmart app enables healthcare consumers to upload content on over 12,500 UK prescription and OTC medicines into their smart device simply by scanning the barcode on the medicine box. This gives a high degree of granularity and specificity to data. Users benefit from curated medicines information presented clearly from SPC documentation, with the support of the MHRA. Smart reminders can be set up to track medicines behaviour for differing patient groups over short or chronic terms.

Adherence

 

Adherence

‘Factors associated with better persistence included older age, male sex, white ethnicity, HbA1c 42-60 mmol/mol, presence of hypertension, no previous glucose-lowering medication use. Non-persistence (was) associated with presence of neuropathy, history of myocardial infarction, heart failure, dementia, depression, and chronic liver disease.’ Medication non-persistence was defined as a ‘prescription gap’ of greater than or equal to 90 days. Non-adherence was identified in 68.5% of study participants, with a median duration of non-adherence of 2.25 years. Metformin drugs such as Glucophage, were found to have the longest crude persistence. Digital tools such as Medsmart®, which provides continuous real-world data insights and patient communication, can enable retrospective studies such as these to become pro-active campaign tools, and deliver the vital information that such studies provide on an ongoing basis. The Medsmart app enables healthcare consumers to upload content on over 12,500 UK prescription and OTC medicines into their smart device simply by scanning the barcode on the medicine box. This gives a high degree of granularity and specificity to data. Users benefit from curated medicines information presented clearly from SPC documentation, with the support of the MHRA. Smart reminders can be set up to track medicines behaviour for differing patient groups over short or chronic terms. Reference: https://www.univadis.co.uk/viewarticle/which-oral-diabetes-medications-are-patients-most-likely-to-keep-taking-579154?spoor=msd_hcv&topic=hcv&u=g7Nnk16ewgvTa0e%2F02zOYWdfC2RBWEYk3JNtV1PSIPrWsb%2BTPEd94oEC3MaC5asource=adhoc%20email&utm_medium=emaign=medical%20updates%20-%20daily%202.5%20gps&utm_content=1944436&utm_term=

Read more at Talking Medicines Health Blog.

 

 

 

 

 

THE TALKING MEDICINES BLOG

Keeping In-Pharmed

Keeping In-Pharmed

As a technology business with a focus on providing pharma marketers with data-based patient intelligence, it’s vital that we stay on top of the big...

read more